Sarcoma Trials

 

• STUDY8700
  
  Molecular Analysis for Therapy Choice (MATCH)
  
  This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
  
  Study Information

  ---

  
  

• STUDY17022
  
  First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
  
  The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
  
  Study Information

  ---

  
  

• STUDY21361
  
  A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
  
  This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation.
  
  Study Information

  ---

  
  

• STUDY21565
  
  A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.)
  
  To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s) To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS], and duration of response [DOR]) of E7386 in combination with other anticancer drug(s) (Revised per Amendment 06)
  
  Study Information

  ---

  
  

• STUDY21654
  
  Feasibility Trial of Preoperative 5 Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
  
  To determine the feasibility of preoperative 5-day HFRT for extremity STS within the HCC patient population Secondary Objectives: To evaluate the rates of favorable pathologic response, major woundcomplications, local control, acute toxicity, and 1-year late toxicity associated with preoperative 5-day HFRT Exploratory Objectives: To compare the socio-demographic profile of trial participants with those of extremity STS patients who would have meet trial criteria and were offered preoperative CFRT in the 3 years prior to the study opening at HCC To compare the retention rate for radiotherapy at HCC in patients meeting trial criteria during the prior 3 years with the retention rate for radiotherapy during the study period To compare serum levels of SFRP2 before and after preoperative 5-day HFRT To evaluate changes in serum SFRP2 levels before and after preoperative 5-day HFRT for an association with favorable pathologic response To evaluate patient satisfaction with the decision to participate in a trial of preoperative 5-day HFRT To assess the importance of the shorter duration of radiotherapy in an individual patient s decision to participate in the study
  
  Study Information

  ---